Can a natural supplement tame prostate cancer? new trial investigates
NCT ID NCT06022822
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a daily supplement called urolithin A can lower oxidative stress in prostate tumors. Ninety men with prostate cancer will take either urolithin A or a placebo for 3 to 6 weeks before their prostate removal surgery. The main goal is to see if the supplement reduces a marker of cell damage in the tumor tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Urolithin A supplement
What this could lead to
If it works, this could point toward a simple dietary supplement that helps control prostate cancer by lowering cell damage.
What could go wrong
This is a small, early-phase trial testing a biomarker, not a cure. The supplement may not affect the cancer itself, and results may not lead to a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Chicago Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Wisconsin Carbone Cancer Center - University Hospital
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact